Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAGNASDAQ:MREONASDAQ:ORKANASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.90-2.6%$1.73$1.33▼$3.58$89.51M0.7361,042 shs3,286 shsMREOMereo BioPharma Group$2.85-0.7%$2.45$1.58▼$5.02$453.15M0.481.09 million shs1.38 million shsORKAOruka Therapeutics$11.68-2.5%$10.76$5.49▼$31.13$437.30M-0.38220,361 shs208,314 shsTECXTectonic Therapeutic$19.81+0.1%$20.99$13.70▼$61.07$369.90M3.26174,957 shs398,720 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%-2.56%+16.92%+12.76%-28.57%MREOMereo BioPharma Group0.00%+3.26%+25.00%+19.75%-28.39%ORKAOruka Therapeutics0.00%-7.01%+4.38%-3.47%+1,167,999,900.00%TECXTectonic Therapeutic0.00%-9.50%-10.77%-6.34%+1,980,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAGAdagene2.5183 of 5 stars3.35.00.00.00.01.70.0MREOMereo BioPharma Group1.2104 of 5 stars3.61.00.00.00.01.70.0ORKAOruka Therapeutics2.7362 of 5 stars3.60.00.00.02.62.50.6TECXTectonic Therapeutic2.7179 of 5 stars3.62.00.00.01.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.50Moderate Buy$8.00321.05% UpsideMREOMereo BioPharma Group 3.20Buy$7.60166.67% UpsideORKAOruka Therapeutics 3.20Buy$40.38245.68% UpsideTECXTectonic Therapeutic 3.25Buy$82.33315.62% UpsideCurrent Analyst Ratings BreakdownLatest ADAG, TECX, ORKA, and MREO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025TECXTectonic TherapeuticRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$76.006/6/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/5/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$44.005/15/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.005/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/13/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/21/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$51.004/9/2025MREOMereo BioPharma GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.004/3/2025ADAGAdageneHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K895.09N/AN/A$1.14 per share1.67MREOMereo BioPharma Group$10M45.32N/AN/A$0.39 per share7.31ORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)MREOMereo BioPharma Group-$43.25M-$0.07N/AN/AN/AN/A-69.33%-57.27%8/12/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%7/30/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$7.31N/AN/AN/AN/A-30.13%-27.52%8/13/2025 (Estimated)Latest ADAG, TECX, ORKA, and MREO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/13/2025Q1 2025MREOMereo BioPharma Group-$0.01-$0.02-$0.01-$0.02$72.50 millionN/A5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/A3/26/2025Q4 2024MREOMereo BioPharma Group$0.02-$0.01-$0.03-$0.01$72.50 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AMREOMereo BioPharma GroupN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.302.30MREOMereo BioPharma GroupN/A8.928.92ORKAOruka TherapeuticsN/A30.0330.03TECXTectonic TherapeuticN/A22.9222.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%MREOMereo BioPharma Group62.83%ORKAOruka Therapeutics56.44%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%MREOMereo BioPharma Group5.50%ORKAOruka Therapeutics24.69%TECXTectonic Therapeutic9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.11 million37.12 millionNot OptionableMREOMereo BioPharma Group40159.00 million150.26 millionOptionableORKAOruka TherapeuticsN/A37.44 million28.20 millionN/ATECXTectonic Therapeutic12018.67 million16.96 millionN/AADAG, TECX, ORKA, and MREO HeadlinesRecent News About These CompaniesTectonic Therapeutic (NASDAQ:TECX) Rating Lowered to "Sell" at Wall Street ZenJune 22 at 1:55 AM | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street ZenJune 21 at 2:54 AM | marketbeat.comWe Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business GrowthJune 15, 2025 | finance.yahoo.comBrokerages Set Tectonic Therapeutic (NASDAQ:TECX) Target Price at $80.50June 13, 2025 | americanbankingnews.comRaymond James Begins Coverage on Tectonic Therapeutic (NASDAQ:TECX)June 12, 2025 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Coverage Initiated by Analysts at Raymond JamesJune 11, 2025 | marketbeat.comTectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock NewsJune 10, 2025 | gurufocus.comTectonic Therapeutic (NASDAQ:TECX) Given Average Recommendation of "Buy" by AnalystsJune 8, 2025 | marketbeat.comLifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationJune 7, 2025 | msn.comTectonic Therapeutic (NASDAQ:TECX) Upgraded at Lifesci CapitalJune 7, 2025 | marketbeat.comTectonic Therapeutic Holds 2025 Annual Stockholders MeetingJune 6, 2025 | tipranks.comLifesci Capital Begins Coverage on Tectonic Therapeutic (NASDAQ:TECX)June 6, 2025 | marketbeat.comTectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock NewsJune 5, 2025 | gurufocus.comMillennium Management LLC Invests $1.33 Million in Tectonic Therapeutic (NASDAQ:TECX)June 4, 2025 | marketbeat.comTectonic Therapeutic Reports Q1 2025 Financial ResultsMay 31, 2025 | tipranks.comWoodline Partners LP Has $6.01 Million Holdings in Tectonic Therapeutic (NASDAQ:TECX)May 26, 2025 | marketbeat.com29,702 Shares in Tectonic Therapeutic (NASDAQ:TECX) Purchased by Jane Street Group LLCMay 22, 2025 | marketbeat.comPromising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45May 22, 2025 | tipranks.comTectonic Therapeutic Announces Phase 1b Trial ResultsMay 19, 2025 | tipranks.comPromising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic TherapeuticMay 19, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)May 17, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADAG, TECX, ORKA, and MREO Company DescriptionsAdagene NASDAQ:ADAG$1.90 -0.05 (-2.56%) Closing price 06/20/2025 03:52 PM EasternExtended Trading$1.92 +0.02 (+0.79%) As of 06/20/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Mereo BioPharma Group NASDAQ:MREO$2.85 -0.02 (-0.70%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.94 +0.09 (+3.33%) As of 06/20/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.Oruka Therapeutics NASDAQ:ORKA$11.68 -0.30 (-2.50%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$11.69 +0.01 (+0.09%) As of 06/20/2025 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Tectonic Therapeutic NASDAQ:TECX$19.81 +0.01 (+0.05%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$19.86 +0.05 (+0.25%) As of 06/20/2025 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
